Organizers



List of participants

back to list
Company

CSIC- Life Sciences Area

Street
Serrano
ZIP Code
28006
City
Madrid
Country
Spain


Company Profile:
The Spanish National Research Council (CSIC) is the largest public research organisation in Spain and the 3rd largest in Europe, covering all science and technology fields through its 128 own and joint centres. CSIC files approx. 180 priority patent applications and signs more than 60 patent licences annually, and collaborates with companies ranging from SMEs to big multinationals.
Profiltitel

Portfolio of CSIC in Life Sciences Area

What we offer:
We offer a wide range of technologies in human and animal health (including several potential drugs and vaccines), diagnostics tools, new materials for health applications, food and agricultural biotechnology, micro and nanotechnologies applied to health, environmental biotechnologies, and the know-how and capacities of our more than 5.000 researchers all sciences and technological fields.

We are open to offer different collaborative approaches, such as exclusive and non-exclusive patent licences, collaborative research, joint ventures and contract research and technical services.

What are we looking for:
We are interested in companies and investors to develop / co-develop and commercialize innovative, mostly IP-protected technologies.
Collaborations based on patent licences (exclusive or non-exclusive, worldwide or geographically limited) are preferred, but we are free to discuss other approaches.
Our technology transfer department is empowered to take decisions on licensing and therefore is eager to consider any proposal on a case-by-case basis.

Keywords:
  • ] Colours, dyes related to Chemicals technology and engineering
  • ] Pharmaceutics
  • ] Special Chemicals, intermediates
  • ] Analytical chemistry
  • ] Biology/Biotechnology
  • ] Micro- and Nanotechnology
  • ] Food additives / Ingredients / Fuctional Food
  • ] Chemical material testing
  • ] Environment


Collaboration sought:
  • Licence Agreement
  • Research and development
  • Technical Co-operation


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Clinical diagnosis (biomarkers for cancer and rheumatoid arthritis)

What we offer:
-Test for cancer diagnosis based on the quantification of acid ceramidase
Use of lysosomal acid ceramidase as biomarker for diagnosis of several types of cancer. The method is based on fluorimetric determination using a specific substrate, thus avoiding interferences and the use of radioactivity, is highly sensitive (pmol) and reduces the analysis time.

-Test for early diagnosis of rheumatoid arthritis based on chimeric fibrin and filaggrin peptides
ELISA test using chimeric citrullinated peptides derived from alpha-fibrin and filaggrin chains for early diagnosis of rheumatoid arthritis. This method, tested with sera from 900 patients, improves sensitivity for diagnosis and may have important prognostic value, identifying patients with aggressive disease and being able to detect the disease when other tests failed.

-Specific apolipoprotein J isoforms as novel biomarkers for acute myocardial infarction
Specific apolipoprotein J isoforms constitute early biomarkers of cardiac ischemic lesion. The levels of these isoforms either increase or decrease up to 50% in the serum of patients with newly acute myocardial infarction (AMI), within 6 hours of onset.

What are we looking for:
Manufacturers of clinical diagnosis kits interested in exploiting these technologies under a patent licence are sought.

Keywords:
  • ] Pharmaceutics
  • ] Analytical chemistry
  • ] Chemical material testing


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Cancer treatment technologies

What we offer:
-Ceramide analogues for cancer therapy
Ceramide analogues, able to inhibit acid ceramidase activity, have been tested in two different human adenocarcinoma cell lines, namely lung A459 and prostate PC-3Mc, with an inhibition of the enzymatic activity of 70-95% at micro and submicromolar concentrations. These compounds have shown capacity to induce an increase in the ceramide levels, causing toxicity in tumour cells and decreasing tumour growth and invasiveness.
These compounds may have application as drugs in cancer therapies, especially in processes with chemoresistance.

- Sp2-iminosugars with potent and selective neutral alpha-glucosidase inhibitory activity as antitumor agents
A family of type sp2 iminosugars selectively inhibits neutral alpha-glycosidases of the endoplasmic reticulum (ER). These amphiphilic iminosugars bear strong potential for therapies targeted at diabetes, viral infections, and specially, cancer. In breast cancer cell lines these compounds inhibit proliferation to 34% at 50 μM and are not cytotoxic.

What are we looking for:
Pharmaceutical companies interested in the development of these technologies under a patent license agreement

Keywords:
  • ] Pharmaceutics


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Rare diseases (Gaucher disease)

What we offer:
- New aminocyclitols for treatment of Gaucher disease
Development of new aminocyclitol derivatives that act as pharmacological chaperones of the mutated glucocerebrosidase enzyme, restoring its activity at nano and subnanomolar concentrations.
These compounds may have application as drugs in the treatment of Gaucher disease, including the lethal type II, which has no treatment yet.
These compounds increase GCase activity between 40-90% on N370S (Type I) and between 20-40% on L444P mutation (Type II).

What are we looking for:
Partners from the pharmaceutical industry are sought for the development and commercialization of the technology under a patent licence.

Keywords:
  • ] Pharmaceutics


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Inflammatory diseases

What we offer:
-New siRNAs conjugated to hydrophobic molecules for silencing gene expression
Development of new small interfering RNA duplexes (siRNA) linked to hydrophobic (lipid, alkyl and aromatic) groups. These siRNA are more stable (specially to nucleases), pass partly through cell membranes even with no transfecting agent and have silenced TNF-α expression in cell cultures, showing its potential to treat inflammatory diseases (IBS, Chron disease)

-Optimization of the therapeutic potential of siRNA by formation of complexes with plasma components
Development of a method to improve small interfering RNA duplexes (siRNA) cell uptake, increasing the inhibition of gene expression without any transfecting reagent. This method is based in the dispersion of plasma components in siRNA, using ultrasounds. The complex increases the potential to use siRNAs in the treatment of inflammatory diseases (IBD) or cancer.

What are we looking for:
Partners from the pharmaceutical industry are sought to develop and commercialize of the technology under a patent licence.

Keywords:
  • ] Pharmaceutics


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Immunomodulation (adjuvants, immune diseases, cancer)

What we offer:
-Aminocyclitol derivatives to regulate immune response by stimulation of natural killer T-cells

Development of new lipid aminocyclitols to promote proliferation of natural killer T-cells, involved in immune responses.
These aminocyclitol derivatives have shown activity to stimulate iNKT cell proliferation by inducing cytokine release both in vitro and in vivo (mice) with a modifiable response in potency in relation to α-GalCer and with extension in the turnaround time. In addition, a highly efficient and potent antitumoral response demonstrates effective Th1 (IFN-gamma) responses in a B16 lung metastasis model.
They have potential as vaccine adjuvants and drugs for autoimmune diseases, infections or cancer.

What are we looking for:
Partners from the pharmaceutical industry are sought for to develop and commercialize the applications of this technology under a patent licence.

Keywords:
  • ] Pharmaceutics


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Neurodegeneration (ictus, ischemia, Alzheimer)

What we offer:
-Maleimide derivatives as potent and versatile GSK-3 inhibitors to treat neurodegenerative and inflammatory diseases, cancer and diabetes
Development of inhibitors of the enzyme GSK-3 acting at nanomolar for compounds with irreversible inhibitory action and micromolar concentrations for those with reversible inhibitory action. These compounds are able to cross the blood brain barrier depending on the chemical substitution.
They are excellent drug candidates for neurodegenerative and inflammatory diseases, cancer, diabetes, and regenerative processes.

-Nitrone derivatives with antioxidant and neuroprotective activity for the treatment of ictus and isquemia
New quinoline nitrone derivatives with elevated antioxidant activity against hydroxyl radicals and lipidic peroxidation, have been prepared. In addition, these compounds present permeability and neuroprotective activity higher than known nitrones like phenyl-t-butyl nitrone (PBN), and are candidates to be used as drugs for Ictus, Ischemia and other neurodegenerative diseases.

What are we looking for:
Partners from the pharmaceutical industry are sought to develop and commercialize these technologies under a patent licence.

Keywords:
  • ] Pharmaceutics


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Regenerative medicine (kidney ischemia)

What we offer:
- Application of lipocalin-2 for jointly reducing inflammation and promoting tissue regeneration in kidney ischemia
Lipocalin-2 (Lcn-2) reduces inflammation and promotes tissue regeneration in kidney following ischemia/reperfusion damage. In vivo assays in mice have shown the potential for this approach by transformation of either macrophages or circulating monocytes to over-express Lcn-2.
Moreover, preliminary results indicate that a “conditioned medium” with combined proteins released from Lcn-2 transformed macrophages is capable to promote kidney tissue repair

What are we looking for:
Pharmaceutical companies interested in the development of this technology under a patent license agreement

Keywords:
  • ] Pharmaceutics


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Food technology (antioxidants)

What we offer:
-Functional oils and fats with high antioxidant content
Design of a process to obtain oils and fats with high antioxidant content, thanks to the inclusion of hydroxytyrosol and hydroxytyrosol fatty acid esters. The process is based on the reaction of hydroxytyrosol, adsorbed on a solid support with either vegetable or animal oil, using an enzymatic catalyst.
This method has a higher yield than others currently available.

-Lipophilic phenolics derivatives as surfactants and antioxidants
Development of compounds derived from the phenolic natural products Tyrosol and Hydroxytyrosol which have surfactant properties similar to other commercial non-ionic surfactants, and moreover, higher antioxidant capacities than many commercial antioxidants (e.g. E307, E310, E320 and E321). The antioxidant activity is particularly stable in biological media.
These compounds could be very useful to develop cosmetic, food, agrochemical, sun protection, personal care and pharmaceutical products.

What are we looking for:
Food or dietetic additive/ingredients manufacturers interested in a patent license and/or collaboration in the development of these technologies are sought.

Keywords:
  • ] Food additives / Ingredients / Fuctional Food


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Food technology (additives)

What we offer:
- Synthesis of phytosterol esters useful in cholesterol reduction, by fungal enzymes
Development of a procedure to obtain phytosterol esters, useful in the reduction of cholesterol blood levels, by a fungal sterol esterase enzyme from Ophiostoma piceae. The enzyme, which can be produced in heterologous expression systems, allows higher yields (up to 90%), in organic solvents or aqueous media, at an optimum temperature of 28ºC (40ºC for other enzymes) and using crude enzyme extracts.

-Zinc salts to improve the preservation of food
Development of a preservative composition for table olives using food-grade zinc salts to control yeast growth. These salts can delay or inhibit the growth of 4 yeast species commonly found in table olives without affecting beneficial lactic bacteria. They are added directly to brines and show higher effect than sorbate for 50 days, thereafter showing a similar effect.

What are we looking for:
Food additive manufacturers or manufacturers of ingredients for foods and dietetic products interested in a patent license and/or collaboration in the development of these technologies are sought.

Keywords:
  • ] Food additives / Ingredients / Fuctional Food


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Pharmaceutical chemistry and industrial biotechnology

What we offer:
- High yield, simpler O-sulphating of heparin precursors in minutes
Development of a method for O-sulphating of glycosaminoglycan and oligosaccharide precursors of heparin analogues. It is faster (reaction times are reduced from days to only minutes), more efficient (higher than 90% yields), simpler (less by-products are generated, making purification easier) and cheaper (lower reagent quantity is required) than current methods.

- Fungal laccases with high potential redox expressed in yeast at elevated concentration and having improved stability and activity
Development of a process to produce fungal laccases with high-redox potential by directed evolution and expression in yeast. A mutant laccase thus produced shows high activity (6-fold higher than that of similar laccases) and stability to the presence of organic solvents, temperature (T50=73ºC) and pH (pH=3-9) and is secreted at 8 mg/L of broth.
High-redox potential laccases have applications in textile, paper and food industries, bioremediation and organic synthesis, and design of 3D nanobiodevices.

What are we looking for:
Chemical or Pharmaceutical companies interested in the development of these technologies under a patent license agreement

Keywords:
  • ] Pharmaceutics
  • ] Biology/Biotechnology


Collaboration sought:
  • Licence Agreement
  • Research and development


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
Profiltitel

Immunoassay to detect residual fluoroquinolone-type antibiotics in food

What we offer:
CSIC has synthesized improved haptens to generate antibodies to fluoroquinolone-based antibiotics for determining their residues in food. The immunoassay is fast and efficient, has detection limits of 0.025-6 ppb depending on the fluoroquinolone, matrix and animal species and detects fluoroquinolones undetectable with other methods.

What are we looking for:
Companies interested in patent licensing and/or in collaborating in the development of its applications are sought.

Keywords:
  • ] Agrochemicals
  • ] Analytical chemistry
  • ] Chemical material testing


Responsible

Ms Dr Isabel Masip

Knowledge Transfer Manager
back to list

Participants

© 2011 ConVerve GmbH | all rights reserved